Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : NHS - Presidential visit strengthens healthcare partnership with Kenya

07/30/2021 | 11:43am EDT

The MoU, signed at the Royal College of Physicians by the Health and Social Care Secretary and Kenya's Cabinet Secretary for Labour Cooperation, Simon Chelugi, and attended by President Uhuru Kenyatta today [Thursday 29 July], builds on UK healthcare support provided to Kenya during the pandemic through the genomic sequencing of positive COVID-19 tests and 817,000 COVID-19 vaccine doses donated this week.

The MoU commits to a process for qualified but unemployed Kenyan nurses to be actively recruited to work in the NHS in the coming years, helping to deliver the government's manifesto commitment for 50,000 more nurses by 2024 and support the training of Kenya's healthcare professionals.

The UK has been working with Kenya for over 30 years to improve healthcare outcomes in both countries, with the Kenya Medical Research Institute (KEMRI) and Wellcome Trust partnering together to establish a health research programme. This partnership has strengthened over the years and has proven to be pivotal throughout the COVID-19 pandemic, with KEMRI and Oxford University working together in trialling the AstraZeneca vaccine, with support from the UK government.

The President's visit to the UK delivers on the Strategic Partnership between the two countries, agreed by President Kenyatta and Prime Minister Boris Johnson in January 2020.

Health and Social Care Secretary, Sajid Javid said: We have a historic and mutually respectful relationship with Kenya. This has been strengthened by working closely with Kenya during the pandemic and sharing UK vaccine doses to support Kenya's fight against COVID-19.

Our healthcare agreement will make the most of UK and Kenyan health expertise which will be beneficial to both countries, with the exchange of knowledge and training which will provide first class healthcare.

The UK is sharing expertise with Kenya to work together in identifying, tracking and responding to new COVID-19 variants, saving lives at home and around the world. KEMRI is working with Public Health England as part of the UK's New Variant Assessment Platform (NVAP). The support includes reagents and equipment to increase in-country genome sequencing, technical advice, support with understanding biological data and training.

As the Prime Minister announced yesterday, the UK will offer 817,000 vaccine doses to Kenya to support efforts to combat the pandemic, with the first doses going this week. This is part of a delivery of 9 million Oxford-AstraZeneca vaccines to COVAX.

Jane Marriott, the British High Commissioner to Kenya, said: Our health partnership with Kenya is over 30 years old and growing stronger by the month. This new agreement on health workers allows us to share skills and expertise even further, and is a fantastic opportunity for Kenyans to work in the UK.

From COVID-19 vaccines and genomic sequencing, to exchanges on cancer research and treatment to help Kenya treatment more cancer patients at home, the UK has a long and proud history of support for Kenya's health sector. The signing of the Kenya-UK Health Alliance is the latest chapter in our flourishing partnership.

Backed by over GBP500m in UK government funding, COVAX, a global scheme to get COVID-19 vaccines to developing countries, has delivered 138 million doses to over 136 countries and territories. COVAX aims to deliver a staggering 1.8 billion COVID-19 vaccines around the world by early 2022.

Following the MoU, an Implementing Committee will develop an Action Plan to identify eligible nurses who may want to apply to work in Health and Care roles in the UK.

With around only 900 Kenyan staff currently in the NHS, the country has an ambition to be the 'Philippines of Africa' - with Filipino staff one of the highest represented overseas countries in the health service - due to the positive economic impact that well-managed migration can have on low to middle income countries.

The MoU also commits the two governments to explore working together to build capacity in Kenya's health workforce through managed exchange and training, depending on funding availability following the Spending Review.

Additionally, the prevention and management of cancer in Kenya will be improved through a partnership between Kenyatta University Teaching Research and Referral Hospital and the University of Manchester/Christie NHS Foundation Trust. In part, this will see the promotion of Kenya as an East African regional hub for cancer treatment.

Background

Kenya took part in vaccine trials of the AstraZeneca vaccine through KEMRI Kilifi, on Kenya's coast, to test the vaccine in different environments.

In the NHS in England there are 894 Kenyans working across all roles. This makes Kenyans the 30th largest nationality group in the NHS.

Contact:

Tel: 0207 210 4850

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ASTRAZENECA PLC
02:29pTHE LATEST : Johnson to Bolsonaro: vaccines save lives
AQ
11:12aEuropean ADRs Move Sharply Lower in Monday Trading
MT
11:07aASTRAZENECA : Imfinzi plus chemotherapy tripled patient survival at three years ..
AQ
11:07aDAIICHI SANKYO : Enhertu reduced the risk of disease progression or death by 72%..
AQ
11:07aDAIICHI SANKYO : Enhertu demonstrated robust and durable tumour response of 54.9..
AQ
10:25aASTRAZENECA : SVB Leerink Adjusts AstraZeneca's PT to $71 from $69, Keeps Outper..
MT
09:53aGRITSTONE BIO : Oncology Doses First Volunteer in Phase 1 Trial of COVID-19 Vacc..
MT
07:58aASTRAZENECA : Credit Suisse remains its Buy rating
MD
07:56aASTRAZENECA : Buy rating from JP Morgan
MD
07:06aASTRAZENECA : Egypt Receives More Than 564k Doses of Covid-19 Vaccine Astrazenec..
AQ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 247 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 31,0x
Yield 2021 2,54%
Capitalization 182 B 181 B -
EV / Sales 2021 5,86x
EV / Sales 2022 4,73x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 110,77 $
Average target price 136,00 $
Spread / Average Target 22,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC10.09%171 794
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604